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Results: Of 634 patients, 387 (61%) underwent PCI. The rates of overall and major
bleeding were 68% and 18% (25% reversal), 39% and 12% (50% reversal), 35% and
9% (75% reversal), and 34% and 7% (100% reversal) compared with 38% and 11%
(heparin). Ischemic events were numerically less frequent in REG1 patients vs. heparin
(4.4% versus 7.3%, p=0.3). Urgent TVR was rare (1%) in both REG1 and heparin
groups.
Conclusion: High level factor IX inhibition coupled with at least 50% reversal of
pegnivacogin activity may represent an attractive strategy in ACS patients undergoing
PCI and deserves testing in adequately powered phase 3 clinical trials.
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Background: Bivalirudin (BIV) has been shown to reduce bleeding complications
compared to unfractionated heparin (UFH) after coronary intervention. The
“Preclosure” technique with a suture-based closure device (VCD) has been reported
to achieve hemostasis after procedures with large caliber arterial sheaths. Clinical
outcomes with BIV, UFH and VCD in balloon aortic valvuloplasty (BAV) have not
been reported.
Methods: In this BAV registry report, we analyzed 354 patients who underwent 432
consecutive procedures (2005-2010) in a single referral center. Univariate and
multivariate logistic regression models were used to evaluate associations between
baseline characteristics, BIV vs. UFH use, VCD vs. manual compression use, and in-
hospital outcomes.
Results: The study cohort is divided in to four groups as shown in the figure. There
were a total of 47 (10.9%) bleeding complications in-hospital: 29 (6.7%) were major
and 18 (4.2%) were minor. The figure shows these results in the 4 groups. There were
no significant differences in the incidence of other vascular complications (group 1:
7.7%, group 2: 3.7%, group 3: 5.3% and group 4: 4.7%; p=0.91) among the four
groups. Among patients who received VCD, those who received UFH (group 2) had
higher mortality compared to those who received BIV (group 4) (8.9% vs. 3.8%,
HR=3.5, 95% CI: 1.2 to 10.2; p=0.025); Among patients treated with BIV, those who
did not receive VCD (group 3) had higher mortality compared to those who received
VCD (group 4) (14.9% vs. 3.8%, HR=4.8, 95% CI: 1.8-12.7; p=0.001).
In-hospital bleeding complications among the four groups.
Conclusion: The combined use of bivalirudin and the “preclosure” technique using
the suture-based VCD was associated with very low bleeding complications after BAV,
and a favorable mortality trend. Fully adjudicated data according to V-ARC and B-
ARC definitions will be presented.
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Background: High on-treatment platelet reactivity (HOPR) in patients on clopidogrel
is associated with adverse events following PCI. The impact of presentation with acute
coronary syndrome (ACS) upon platelet reactivity, however, is not well-understood.
Methods: Patients received 600 mg clopidogrel and 325 mg aspirin at the time of PCI
and underwent platelet reactivity testing with Vasodilator Stimulated Phosphoprotein
Phosphorylation (VASP) 6-24 hours after PCI. HOPR was defined as VASP platelet
reactivity index >50%. ACS was defined as ≥2 of the following: 1) symptoms
consistent with myocardial ischemia; 2) ST elevation or depression ≥1 mm in ≥2
contiguous leads on EKG; 3) cardiac troponin level above upper limit of normal. VASP
platelet reactivity index and HOPR were compared between groups using the Wilcoxon
and Chi-square tests, respectively. Multivariable logistic regression was used to assess
the independent effect of ACS upon HOPR.
Results: 377 patients were enrolled, of whom 12.9% presented with ACS. Patients
with ACS were less likely to have a history of CAD (22.4% v. 59.8%) or previous PCI
(12.5 v. 46.6%) and more likely to have a history of congestive heart failure (22.4%
vs. 11.6%) or a left anterior descending lesion (47.8% v. 30.2%; p <0.001 for all
comparisons). Median VASP platelet reactivity index was higher in ACS patients
(52.6% v. 38.3%, p=0.02), as was incidence of HOPR (55.1% v. 34.6%, p=0.007).
Following multivariable adjustment, ACS remained significantly associated with
HOPR (OR 2.18, 95% CI 1.15-4.12, p=0.02; Table).
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Conclusion: Presentation with ACS is a significant risk factor for HOPR. Platelet
reactivity testing should focus on such high-risk patients.
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Bleeding During Dual Antiplatelet Therapy
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Background: Drug eluting stent implantation in patients with high risk for bleeding
is a relative clinical contraindication according to recent guidelines of the European
Society of Cardiology. On the other hand, the stent restenosis limits 20-30% of
percutaneous coronary interventions with bare metal stents implantations. Our aim is
to examine the outcome of CD 34 antibody coated stent (GENOUS, Orbus Neich) in
a group of patient with high risk for bleeding during prolonged dual antiplatelet therapy.
Methods: In our database we have identified, 61 consecutive patients with mean age
65,5±19 years, who electively received a GENOUS stent during the period June 2006
to July 2009, in whom dual antiplatelet therapy* (*DAPT: Aspirin 100mg and
Clopidogrel 75mg) had to be limited for various periods due to accompanied diseases
and/or surgical needs. The survey excluded patients with STEMI and NSTEMI. 35
patients (57%) had DAPT for a maximum of 4 weeks while 26 patients (43%) had a
DAPT of 2 to 12 months.
Results: Please find attached the results
Results
* Target lesion revascularisation
**Major adverse cardiac events
Conclusion: In patients with contraindications to long antiplatelet therapy for
accompanying diseases, GENOUS Stent demonstrates a good alternative and is
associated with significant benefits in terms of TLR and stent thrombosis. Thus until
the results of further large randomized trials with long-term follow up become
available, GENOUS stent may be considered among patients with high risk of bleeding
undergoing primary angioplasty.
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Background: CABG surgery within 5 days of antiplatelet treatment discontinuation
is controversial. We aimed to evaluate the association of on-treatment platelet reactivity
before CABG and in-hospital major bleeding (IHMB).
Methods: On-treatment platelet reactivity was prospectively measured with Verify
Now (VN) P2Y12 assay, Vasodilator Stimulated Phosphoprotein Phosphorylation
(VASP) and Light Transmittance Aggregometry (LTA) with 5 and 20 μM of ADP, in
51 patients undergoing CABG within 5 days of thienopyridine discontinuation, from
08/2010 to 05/2011. The primary endpoint was IHMB, defined as bleeding
intracranially, or that associated with hemodynamic compromise, a hemoglobin (Hb)
drop of >5g/dl, or a hematocrit drop of >15%. We assessed the relation between platelet
reactivity value and IHMB with Wilcoxon rank-sum test and its relation with Hb drop
with Spearman correlation.
Results: Average age was 62 years. Thirty patients (58.8%) had major bleeding. Only
VASP and LTA 5 μM of ADP were associated with the primary endpoint (p=0.001 and
0.03, respectively). Median VASP platelet reactivity index (PRI) was 56.7% in patients
with IHMB and 73.7% in those without. The respective values of maximal platelet
aggregation percentage by LTA 5 μM were 39% and 48%. VN P2Y12 reaction units
and VASP PRI were inversely correlated to the degree of hemoglobin drop after CABG
(p= 0.0006 and 0.0012, respectively).
Conclusion: Platelet reactivity testing with VASP and LTA 5 μM of ADP before CABG
is associated with IHMB. These tests could be used to risk stratify patients undergoing
CABG within 5 days of thienopyridine discontinuation.
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Background: The impact of paraoxonase-1 (PON1) activity and PON1 gene
polymorphism on the efficacy of clopidogrel has not been clarified. The aim of this
study was to assess the association of PON1 activity and the incidence of intra-stent
thrombus after drug-eluting stent (DES) implantation in the Japanese CYP2C19*2
carriers and non-carriers receiving clopidogrel.
Methods: This study included 48 Japanese patients who underwent optical coherence
tomography (OCT) examination for the evaluation of intra-stent thrombus 8 months
after DES implantation. The patients were chronically treated with clopidogrel
(75mg/day) and aspirin (100mg/day). The CYP2C19 genotype was analyzed by
polymerase chain reaction and the PON1 activity was evaluated by spectrophotometric
assay. The patients were divided into two groups; those with at least one CYP2C19*2
allele (*2 carriers) and non-carriers.
Results: In 48 Japanese patients, 19 patients were *2 carriers. In *2 carriers, the
incidence of intra-stent thrombus was 52.6% (p=0.03 vs non-carriers). The PON1
activity was lower in *2 carriers with intra-stent thrombus than those without intra-
stent thrombus (178±53 U/L vs 257±102 U/L, p=0.04). In non-carriers, the incidence
of intra-stent thrombus was less (20.7%), and the PON1 activity was not different
between non-carriers with intra-stent thrombus or those without intra-stent thrombus
(227±35 U/L vs 226±102 U/L, p>0.99).
Conclusion: The PON1 activity influenced the incidence of intra-stent thrombus in
CYP2C19*2 carriers, but did not influence that in non-carriers. This study suggested
that the PON1 activity may have an impact on clopidogrel efficacy in Asians, because
of the high frequency of CYP2C19*2 polymorphism.
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